Treatment of Resistant Gram-Negative Bacterial Infections

Recommended Treatment Options

• The Infectious Diseases Society of America recommends aztreonam combined with ceftazidime-avibactam as the preferred treatment for metallo-β-lactamase-producing Carbapenem-Resistant Enterobacterales, with significantly lower 30-day mortality (19.2% vs 44%) compared to other treatment options 1, 2
• Aztreonam is uniquely active against metallo-β-lactamase-producing CRE as it is not hydrolyzed by these enzymes, though as monotherapy it does not cover other beta-lactamases often co-produced by such strains 3, 4

Mechanism of Action

• Aztreonam demonstrates stability against many beta-lactamases, making it valuable for treating certain resistant gram-negative infections 3, 4